Saudi hires HMG veteran behind $21.9B group to run care for 33M people

Saudi Arabia has put Nasser Al Huqbani, the former chief executive behind Dr. Sulaiman Al Habib Medical Group, in charge of a state health system serving more than 33 million people, according to Dealroom.co.

The appointment matters for UAE healthcare groups because Saudi Arabia is turning public delivery into cluster-based operating companies. For Dubai hospital owners, insurers and medical tourism teams, the question is practical: will Saudi patients still travel, or will HHC keep more complex care inside Riyadh, Jeddah and the Eastern Province?

What Saudi Arabia hired

Dealroom.co reported on 5 September 2026 that Al Huqbani became chief executive officer of Health Holding Company in January 2023. HHC oversees more than 20 million registered beneficiaries across 20 autonomous health clusters. The Saudi Cabinet transferred Ministry of Health assets to HHC in August 2022.

Al Huqbani spent 26 years building HMG into Saudi Arabia's largest private healthcare operator. By his departure in October 2022, Dealroom.co said HMG had more than 1,900 beds, more than 14,000 staff and more than 5.3 million patients a year.

The capital-markets record is the signal for CFOs. HMG floated 15% of its shares in March 2020 at SAR 50 a share, Dealroom.co reported. The offer was about 83 times oversubscribed and drew nearly $57.9 billion in orders. Dealroom.co put HMG's market capitalisation at $21.9 billion in August 2026, with shares up about 5.2 times since listing.

Why Dubai should watch first

Dubai providers regulated by the Dubai Health Authority (DHA) face the earliest commercial test. Saudi self-pay and insured patients have long been part of Dubai's private hospital mix, especially for elective specialties, second opinions and branded care. If HHC clusters improve referral pathways and contracting discipline, Dubai operators may see slower inbound growth in services that can be repatriated to Saudi hospitals.

For insurers, the issue is network leverage. UAE payers such as Sukoon, and Abu Dhabi schemes and administrators such as Daman and Thiqa, should track whether Saudi-linked employers start asking for cross-border packages priced against HMG and HHC benchmarks. The finance team should compare UAE episode costs against Saudi alternatives by procedure, length of stay, readmission rate and approval time.

• CEOs should review Saudi referral exposure by specialty and payer by Q4 2026.
• CFOs should benchmark inpatient packages against Saudi private hospital prices where payer data is available.
• COOs should test whether Saudi patient intake depends on concierge access, Arabic records, or post-discharge coordination.
• CMOs should separate Saudi medical-travel campaigns by specialty rather than using general hospital advertising.

Abu Dhabi and the northern emirates

In Abu Dhabi, the Department of Health Abu Dhabi (DOH Abu Dhabi) already regulates a market with large public assets, tertiary hospitals and managed insurance channels. HHC's model is relevant because Abu Dhabi operators compete on complex care and outcomes, not only hotel-style service. Any Saudi progress in tertiary capacity could affect referrals into Abu Dhabi for cardiology, oncology, transplant-related reviews and high-acuity second opinions.

For Sharjah, Ajman, Ras Al Khaimah, Fujairah and Umm Al Quwain, the relevant regulator is the Ministry of Health and Prevention (MOHAP). Northern emirates clinics should watch for a different effect: Saudi reforms may raise patient expectations for digital booking, virtual follow-up and unified records. Dealroom.co cited HMG's 2017 launch of Saudi Arabia's first fully digital hospital and its 2019 Tele-ICU command centre monitoring 796 beds across the GCC.

The limitation is clear. Saudi Arabia's public-system reform does not automatically move UAE reimbursement, licensing or clinical rules. DHA, DOH Abu Dhabi and MOHAP remain the authorities for UAE facility licensing, professional licensing and health advertising. Operators should use regulator portals and payer contracts for local compliance dates, rather than reading Saudi timelines across the border.

The next indicator is procurement. If HHC clusters gain financial autonomy, Saudi tenders may pull vendors, clinicians and management talent away from the UAE. UAE boards should ask management for a 2027 exposure note covering Saudi patient volumes, Saudi consultant recruitment risk and payer requests for cross-border tariffs.

Patients and operators comparing licensed hospitals in Dubai, Abu Dhabi and the northern emirates can start with the UAE Open Healthcare Directory, which lists licensed hospital providers and helps verify location, specialty and regulator coverage before referral or contracting decisions.